North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
|Articles|March 11, 2021
COPD Stakeholder Summit—Individualizing Treatment and Improving Outcomes, Part 1
In part 1 of the COPD Stakeholder Summit, a panel of experts about the burden of COPD, available treatments, and more.
Advertisement
This activity is supported by an educational grant from Boehringer Ingelheim.
Today, we are bringing you part 1 of a 2-part podcast series discussing chronic obstructive pulmonary disease (COPD). In part 1, moderator Neil Minkoff, MD, chief medical officer of Coeus Healthcare, leads a discussion with a panel of experts about the burden of COPD, available treatments, and more.
Listen above or through one of these podcast services:
Advertisement
Related to this article
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
Advertisement
Advertisement